Cidara Therapeutics (CDTX) Competitors $67.49 +2.46 (+3.78%) Closing price 04:00 PM EasternExtended Trading$68.24 +0.75 (+1.11%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. RYTM, RNA, NUVL, ABVX, AXSM, CRSP, MRUS, VKTX, TGTX, and ACADShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Merus (MRUS), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Its Competitors Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Abivax Axsome Therapeutics CRISPR Therapeutics Merus Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals Rhythm Pharmaceuticals (NASDAQ:RYTM) and Cidara Therapeutics (NASDAQ:CDTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media prefer RYTM or CDTX? In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Cidara Therapeutics. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 2 mentions for Cidara Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 1.02 beat Cidara Therapeutics' score of 0.94 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend RYTM or CDTX? Rhythm Pharmaceuticals currently has a consensus price target of $101.57, indicating a potential downside of 0.11%. Cidara Therapeutics has a consensus price target of $64.14, indicating a potential downside of 4.96%. Given Rhythm Pharmaceuticals' higher probable upside, equities analysts clearly believe Rhythm Pharmaceuticals is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has better earnings & valuation, RYTM or CDTX? Cidara Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M51.90-$260.60M-$3.01-33.78Cidara Therapeutics$1.27M1,347.67-$169.83M-$11.13-6.06 Is RYTM or CDTX more profitable? Cidara Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Cidara Therapeutics' return on equity of -50.81% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-117.13% -1,831.43% -48.33% Cidara Therapeutics N/A -50.81%-42.46% Which has more volatility & risk, RYTM or CDTX? Rhythm Pharmaceuticals has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Do insiders & institutionals believe in RYTM or CDTX? 35.8% of Cidara Therapeutics shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryRhythm Pharmaceuticals and Cidara Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-6.0620.4330.4625.16Price / Sales1,347.67238.53392.5787.62Price / CashN/A42.3737.0358.50Price / Book3.427.918.956.21Net Income-$169.83M-$54.72M$3.26B$265.38M7 Day Performance6.20%1.66%1.06%-1.13%1 Month Performance18.30%5.88%4.31%-0.71%1 Year Performance419.15%8.72%28.39%18.86% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics3.5373 of 5 stars$67.49+3.8%$64.14-5.0%+402.2%$1.71B$1.27M-6.0690RYTMRhythm Pharmaceuticals3.7235 of 5 stars$94.31+2.5%$101.57+7.7%+116.4%$6.11B$130.13M-31.33140News CoveragePositive NewsRNAAvidity Biosciences3.1565 of 5 stars$45.75-1.2%$67.00+46.4%-1.2%$5.96B$10.90M-15.25190News CoverageOptions VolumeNUVLNuvalent3.3793 of 5 stars$74.95+1.1%$119.60+59.6%-4.0%$5.32BN/A-15.3040News CoverageAnalyst ForecastInsider TradeABVXAbivax2.5854 of 5 stars$69.00-1.6%$92.33+33.8%+531.7%$5.30BN/A0.0061Short Interest ↑AXSMAxsome Therapeutics4.7766 of 5 stars$103.96-0.8%$178.00+71.2%+32.7%$5.23B$385.69M-20.50380Positive NewsCRSPCRISPR Therapeutics3.769 of 5 stars$55.41+0.7%$71.60+29.2%+8.2%$5.00B$37.31M-10.20460Positive NewsMRUSMerus2.2018 of 5 stars$64.60+0.9%$88.50+37.0%+20.0%$4.84B$36.13M-11.7537News CoverageVKTXViking Therapeutics3.967 of 5 stars$38.20+0.8%$86.92+127.6%-61.2%$4.26BN/A-24.9620Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3111 of 5 stars$26.39-1.2%$46.25+75.3%+14.6%$4.24B$329M71.32290Positive NewsACADACADIA Pharmaceuticals3.9108 of 5 stars$24.82+0.9%$28.88+16.3%+60.2%$4.15B$957.80M18.66510Insider Trade Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Nuvalent Competitors Abivax Competitors Axsome Therapeutics Competitors CRISPR Therapeutics Competitors Merus Competitors Viking Therapeutics Competitors TG Therapeutics Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access